• Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality 

      Evans, Dafydd Gareth; Harkness, Elaine F.; Howell, Anthony; Wilson, Mary; Hurley, Emma; Holmen, Marit Muri; Tharmaratnam, Kukatharmini; Hagen, Anne Irene; Lim, Yit Yoong; Maxwell, Anthony James; Møller, Pål (Peer reviewed; Journal article, 2016)
      Background The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast ...
    • Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences 

      Valla, Marit; Vatten, Lars Johan; Engstrøm, Monica J; Haugen, Olav Anton; Akslen, Lars A.; Bjørngaard, Johan Håkon; Hagen, Anne Irene; Ytterhus, Borgny; Bofin, Anna M.; Opdahl, Signe (Journal article; Peer reviewed, 2016)
      Background: Secular trends in incidence and prognosis of molecular breast cancer subtypes are poorly described. We studied long-term trends in a population of Norwegian women born 1886–1977. Methods: A total of 52,949 ...
    • Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients 

      Engstrøm, Monica J; Opdahl, Signe; Hagen, Anne Irene; Romundstad, Pål Richard; Akslen, Lars A.; Haugen, Olav A.; Vatten, Lars Johan; Bofin, Anna M. (Peer reviewed; Journal article, 2013)
      Molecular subtyping of breast cancer may provide additional prognostic information regarding patient outcome. However, its clinical significance remains to be established. In this study, the main aims were to discover ...
    • Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial 

      Ausen, Kjersti; Hagen, Anne Irene; Sæther Østbyhaug, Heidi; Olafsson, Sverrir; Kvalsund, Berit; Spigset, Olav; Pleym, Hilde (Journal article; Peer reviewed, 2019)
      Background: Topical administration of tranexamic acid (TXA) may be an alternative to intravenous administration to reduce bleeding with a lower risk of systemic adverse events. The aim of this study was to investigate ...